Kedrion S.p.A.

Eliem prices $80M IPO, plus updates from Moderna, Arcturus, Liminal, Sydnexis and LQT

In FDA’s first approval of a new therapy for chronic weight management since 2014, the agency approved GLP-1 analog Wegovy semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO). The

Luciano Rossetti will retire at year-end from Merck KGaA (Xetra:MRK) after a six-year tenure as global head of R&D for the healthcare business sector. Rossetti’s